Posts – Page 79 – Safe Biologics

Biosimilars Policy Forum: Ensuring Patient Safety

August 1, 2011

Alliance for Safe Biologic Medicines & Pennsylvania Bio
August 17, 2011
The Quorum at the University Science Center
Philadelphia, PA

Rethink regulations for new drug therapies

July 28, 2011

Orange County Register
By Thair Phillips, President, RetireSafe

The biotech revolution has brought hope to millions of Americans coping with some of the most devastating medical conditions, including cancer, Parkinson’s disease and rheumatoid arthritis. New prescription drugs, known as biologics, that were born of this revolution now comprise the fastest-growing segment of the pharmaceutical market and could account for half of all new drugs approved by 2015.

With intense pressure on governments to control rising health care costs, a push is underway to introduce lower-cost biotech medicines that function more or less as equivalents of these biologics. But a host of complicating factors surrounding biologics – not least of which is patient safety – have doctors, patients, drug companies, and regulators trying to work through the thorny problems unique to these drugs.

Rethink regulations for new drug therapies

July 28, 2011

Orange County Register
By Thair Phillips, President, RetireSafe

The biotech revolution has brought hope to millions of Americans coping with some of the most devastating medical conditions, including cancer, Parkinson’s disease and rheumatoid arthritis. New prescription drugs, known as biologics, that were born of this revolution now comprise the fastest-growing segment of the pharmaceutical market and could account for half of all new drugs approved by 2015.

With intense pressure on governments to control rising health care costs, a push is underway to introduce lower-cost biotech medicines that function more or less as equivalents of these biologics. But a host of complicating factors surrounding biologics – not least of which is patient safety – have doctors, patients, drug companies, and regulators trying to work through the thorny problems unique to these drugs.